Penumbra reported Q4 sales of $315.52 million, up 10.8% Y/Y, beating estimates of $311.55 million. U.S. thrombectomy sales jumped 27.3%, driving global growth of 15.4%. Next: Get access to a new ...
Penumbra, Inc. PEN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 97 cents, which surpassed the Zacks Consensus Estimate by 6.5%. Adjusted EPS improved 27.6% year over year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback